Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatographyCHIN, David L; LUM, Bert L; SIKIC, Branimir I et al.Journal of chromatography. B, Biomedical sciences and applications. 2002, Vol 779, Num 2, pp 259-269, issn 1387-2273, 11 p.Article

Quantitative structure-activity relationships of methotrexate and methotrexate analogues transported by the rat multispecific resistance-associated protein 2 (rMrp2)NG, Chee; XIAO, Yun-De; LUM, Bert L et al.European journal of pharmaceutical sciences. 2005, Vol 26, Num 5, pp 405-413, issn 0928-0987, 9 p.Article

Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancerCOSSON, Valérie F; NG, Vivian W; LEHLE, Michaela et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 4, pp 737-747, issn 0344-5704, 11 p.Article

Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib studyNA XU; REDFERN, Charles H; GORDON, Michael et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 6, pp 1251-1260, issn 0344-5704, 10 p.Article

Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeysLU XU; ZUCH, Christina L; LIN, Yvonne S et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 4, pp 607-614, issn 0344-5704, 8 p.Article

Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): Early termination due to increased toxicitiesMESSERSMITH, Wells A; LAHERU, Daniel A; SENZER, Neil N et al.Clinical cancer research. 2004, Vol 10, Num 19, pp 6522-6527, issn 1078-0432, 6 p.Article

Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in Patients with advanced malignanciesADVANI, Ranjana; FISHER, George A; LUM, Bert L et al.Clinical cancer research. 2003, Vol 9, Num 14, pp 5187-5194, issn 1078-0432, 8 p.Article

Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein BindingGRAHAM, Richard A; LUM, Bert L; CHEETI, Sravanthi et al.Clinical cancer research (Print). 2011, Vol 17, Num 8, pp 2512-2520, issn 1078-0432, 9 p.Article

Long-term results of irradiation for patients with progressive Graves' ophthalmopathyMARQUEZ, Sheri D; LUM, Bert L; MCDOUGALL, I. Ross et al.International journal of radiation oncology, biology, physics. 2001, Vol 51, Num 3, pp 766-774, issn 0360-3016Article

Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy malesWYNNE, Chris J; ELLIS-PEGLER, Rod B; LUM, Bert L et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 5, pp 1079-1087, issn 0344-5704, 9 p.Article

A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistanceADVANI, Ranjana; FISHER, George A; LUM, Bert L et al.Clinical cancer research. 2001, Vol 7, Num 5, pp 1221-1229, issn 1078-0432Article

The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjectsHAMILTON, Marta; WOLF, Julie L; DROLET, Daniel W et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 3, pp 613-621, issn 0344-5704, 9 p.Article

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancerLU, Jian-Feng; EPPLER, Steve M; WOLF, Julie et al.Clinical pharmacology and therapeutics. 2006, Vol 80, Num 2, pp 136-145, issn 0009-9236, 10 p.Article

A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21-day infusion to patients with advanced ovarian carcinomaADVANI, Ranjana; PEETHAMBARAM, Prema; LUM, Bert L et al.Cancer. 2004, Vol 100, Num 2, pp 321-326, issn 0008-543X, 6 p.Article

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced CancerHERBST, Roy S; ECKHARDT, S. Gail; ASHKENAZI, Avi et al.Journal of clinical oncology. 2010, Vol 28, Num 17, pp 2839-2846, issn 0732-183X, 8 p.Article

The effects of CYP3A4 inhibition on erlotinib pharmacokinetics : computer-based simulation (SimCYP™) predicts in vivo metabolic inhibitionRAKHIT, Ashok; PANTZE, Michael P; FETTNER, Scott et al.European journal of clinical pharmacology. 2008, Vol 64, Num 1, pp 31-41, issn 0031-6970, 11 p.Article

Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancerHARTMAN, Anne-Renee; GREKOWICZ, Amy; LUM, Bert L et al.Breast cancer research and treatment. 2003, Vol 82, Num 1, pp 61-69, issn 0167-6806, 9 p.Article

Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjectsGRAHAM, Richard A; HOP, Cornelis E. C. A; BORIN, Marie T et al.British journal of clinical pharmacology. 2012, Vol 74, Num 5, pp 788-796, issn 0306-5251, 9 p.Article

A Single Dose Mass Balance Study of the Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Humans Using Accelerator Mass SpectrometryGRAHAM, Richard A; LUM, Bert L; MINLI XIE et al.Drug metabolism and disposition. 2011, Vol 39, Num 8, pp 1460-1467, issn 0090-9556, 8 p.Article

Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteersJIE LING; JOHNSON, Kim A; ZHUANG MIAO et al.Drug metabolism and disposition. 2006, Vol 34, Num 3, pp 420-426, issn 0090-9556, 7 p.Article